Etoposide

Generic Name: Etoposide

Brand Names: Etopophos, Toposar, Vepesid

Drug Type: Small Molecule

Chemical Formula: C_₂₉H_₃₂O_₁₃

CAS Number: 33419-42-0

Unique Ingredient Identifier: 6PLQ3CP4P3

Background: A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.

Indication: For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer

Associated Therapies: -

Clinical Trials

A Study of BMS-833923 With Carboplatin and Etoposide Followed by BMS-833923 Alone in Subjects With Extensive-Stage Small Cell Lung Cancer

Phase 1

Completed

Conditions: Small Cell Lung Carcinoma

Interventions: Drug: BMS-833923
Drug: Carboplatin
Drug: Etoposide

First Posted Date: 2009-06-25

Last Posted Date: 2013-06-03

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 5

Registration Number: NCT00927875

Locations: 🇮🇪
Local Institution, Dublin, Ireland
🇺🇸
Karmanos Cancer Institute, Detroit, Michigan, United States

A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers

Phase 1

Completed

Conditions: Carcinoma Neuroendocrine
Small Cell Lung Carcinoma
Malignant Epithelial Neoplasms

Interventions: Drug: Belinostat
Drug: Cisplatin
Drug: Etoposide

First Posted Date: 2009-06-23

Last Posted Date: 2018-10-19

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 28

Registration Number: NCT00926640

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

A Phase II Study of Neo-Adjuvant Gemcitabine, Cisplatin and Bevacizumab in Stage IIIA (N2) Non-Squamous Cell Non-Small Cell Lung Cancer

Phase 2

Terminated

Conditions: NSCLC
Stage IIIA (N2)

Interventions: Drug: Gemcitabine
Drug: Cisplatin
Drug: Bevacizumab
Procedure: Surgery
Drug: Etoposide

First Posted Date: 2009-06-18

Last Posted Date: 2018-11-30

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 7

Registration Number: NCT00924209

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
🇭🇷
University Hospital for Lung Diseases, Zagreb, Croatia

Three Different Therapy Regimens in Treating Patients With Previously Untreated Hodgkin Lymphoma

Phase 3

Terminated

Conditions: Lymphoma

Interventions: Biological: bleomycin sulfate
Drug: ABVD regimen
Drug: cisplatin
Drug: carmustine
Drug: cytarabine
Drug: dacarbazine
Drug: dexamethasone
Drug: doxorubicin hydrochloride
Drug: etoposide
Drug: gemcitabine hydrochloride
Drug: vincristine sulfate
Drug: ifosfamide
Drug: vindesine
Drug: melphalan
Drug: methylprednisolone
Drug: mitoguazone
Drug: vinorelbine tartrate
Procedure: allogeneic hematopoietic stem cell transplantation
Procedure: autologous hematopoietic stem cell transplantation

First Posted Date: 2009-06-15

Last Posted Date: 2016-09-16

Lead Sponsor: French Innovative Leukemia Organisation

Target Recruit Count: 442

Registration Number: NCT00920153

Locations: 🇫🇷
FILO French Innovative Leukemia Organization, Tours Cedex, France

A Randomized Study to Evaluate the Effect of Two Different Doses of Enoxaparin Sodium in Combination With Standard Chemotherapy in Patients With Stage Small Cell Lung Cancer (SCLC)

Phase 2

Withdrawn

Conditions: Small Cell Lung Cancer

Interventions: Drug: Etoposide
Drug: Cisplatin
Drug: enoxaparin sodium

First Posted Date: 2009-06-09

Last Posted Date: 2013-05-08

Lead Sponsor: Massachusetts General Hospital

Registration Number: NCT00916669

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
North Shore Medical Center, Peabody, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

and more 1 locations

Carmustine, Etoposide, Cytarabine, Melphalan, and Alemtuzumab Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Phase 2

Conditions: Lymphoma

First Posted Date: 2009-05-25

Last Posted Date: 2013-08-02

Lead Sponsor: Cancer Research UK

Target Recruit Count: 47

Registration Number: NCT00908180

Chemosensitization With Plerixafor Plus G-CSF in Acute Myeloid Leukemia

Phase 1

Completed

Conditions: Leukemia, Myeloid, Acute

Interventions: Drug: G-CSF
Drug: Plerixafor
Drug: Mitoxantrone
Drug: Etoposide
Drug: Cytarabine

First Posted Date: 2009-05-21

Last Posted Date: 2017-04-04

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 39

Registration Number: NCT00906945

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Washington University, St. Louis, Missouri, United States
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

A Randomized Phase II Study of Cisplatin and Etoposide in Combination With Either Hedgehog Inhibitor GDC-0449 or IGF-1R MOAB IMC-A12 for Patients With Extensive Stage

Phase 2

Completed

Conditions: Extensive Stage Small Cell Lung Carcinoma
Recurrent Small Cell Lung Carcinoma

Interventions: Drug: Cisplatin
Biological: Cixutumumab
Other: Laboratory Biomarker Analysis
Drug: Etoposide
Drug: Vismodegib

First Posted Date: 2009-04-23

Last Posted Date: 2021-01-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 168

Registration Number: NCT00887159

Locations: 🇺🇸
Boca Raton Regional Hospital, Boca Raton, Florida, United States
🇺🇸
Mason District Hospital, Havana, Illinois, United States
🇺🇸
Longmont United Hospital, Longmont, Colorado, United States

and more 297 locations